Charlie's Q2 FY26 operating loss widens to $1.23 million; revenue more than doubled to $3.8 million

• Charlie's Holdings posted Q2 revenue of $3.8 million, more than doubled from a year earlier.
• Net loss widened to $1.66 million from net income a year earlier, when results included a $6.5 million gain on IP sales.
• Operating loss widened to $1.23 million as total operating costs and expenses climbed 63.3% to $2.35 million.
• Gross profit rose to $1.12 million, while revenue growth was driven by higher nicotine-based and nicotine-alternative product sales, including SBX.
• FDA flagged 30 PACHA SKUs for a “low-enforcement priority” list, while Charlie's plans an age-gated disposable test launch in Q3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charlie's Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-028182), on August 17, 2026, and is solely responsible for the information contained therein.